{"id":14373,"date":"2011-12-12T10:30:00","date_gmt":"2011-12-12T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmaceutici-credit-suisse-promuove-roche-a-outperform-bayer-vede-tp-salire-a-56-euro\/"},"modified":"2011-12-12T10:30:00","modified_gmt":"2011-12-12T09:30:00","slug":"farmaceutici-credit-suisse-promuove-roche-a-outperform-bayer-vede-tp-salire-a-56-euro","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaceutici-credit-suisse-promuove-roche-a-outperform-bayer-vede-tp-salire-a-56-euro\/","title":{"rendered":"Pharmaceuticals: Credit Suisse promotes Roche to outperform, Bayer sees tp rise to 56 euros"},"content":{"rendered":"<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><em><span style=\"line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\">Finanzaonline.com \u2013 12.12.11\/11:05<\/span><\/em><span style=\"line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black\"><br \/> <font size=\"3\"><span class=\"testo1\"><span style=\"line-height: 115%; mso-ansi-font-size: 11.0pt; mso-bidi-font-size: 11.0pt\">European drug stocks end up under the magnifying glass of Credit Suisse, which is putting its hand to evaluating some big names in the sector. According to the Swiss broker, 2012 will reserve new challenges for pharmaceutical companies in Europe but the diversification and development strategies adopted so far in emerging countries and the launch of new products will be able to support their profits. Not only. There is record investment in corporate restructuring and removal of cost overruns, while balance sheets are strong enough to compensate shareholders. Against this positive backdrop, Credit Suisse lists Novartis, Bayer and Roche as the preferred companies. In particular, on Bayer, analysts raise the target price to 56 euros from the previous 53 euros, because &quot;the weak sales of Yaz\/Yasmine and the launch costs of Xarelto, which will have an impact on 2012, are already largely discounted by the stock&quot;. On the other hand, the promotion (from neutral to outperform) arrives on Roche, thanks to the defensive strategy of the group which should allow for the distribution of a dividend to shareholders. Neutral rating confirmed on Sanofi, Novo Nordisk and GlaxoSmithKline. Avoid instead Astrazeneca (rating underperform): &quot;we expect the company to cut its Research and Development activity in 2012&quot;. <\/span><\/span><\/font><\/span><span style=\"line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\"><br \/> <span class=\"testo1\">Source: Finanza.com<\/span><\/span><\/span><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><em style=\"mso-bidi-font-style: normal\"><span style=\"line-height: 115%; font-size: 9pt\"><\/p>\n<p><a target=\"_self\" href=\"http:\/\/www.finanzaonline.com\/\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" style=\"width: 452px; height: 49px\" border=\"0\" alt=\"\" width=\"982\" height=\"80\" src=\"http:\/\/img.finanzaonline.com\/img\/testata.jpg\" \/><\/a><\/p>\n<p><\/span><\/em><\/p>\n<p>&nbsp; <\/p>\n<table summary=\"story body\">\n<tbody>\n<tr>\n<td colspan=\"2\">\n<h1 class=\"headlineLargeBlue\">Broker snap: Credit Suisse reiterates underperform on AstraZeneca<\/h1>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n<p class=\"textSmallRed\">Mon 12 Dec 2011<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\"><!-- story introduction --><\/p>\n<style type=\"text\/css\">  \t\t\t\ttable.border_total_side \t\t\t\t{ \t\t\t\t\tfloat:right; \t\t\t\t\tmargin-left: 10px; \t\t\t\t}\t\t \t\t\t<\/style>\n<table class=\"border_total_side\" border=\"0\" cellspacing=\"1\" cellpadding=\"0\" width=\"180\" align=\"left\">\n<tbody>\n<tr>\n<td>\n<table border=\"0\" cellspacing=\"1\" cellpadding=\"1\" width=\"100%\">\n<tbody>\n<tr class=\"bgcolorgen\">\n<td class=\"tableHeadingWhite\" colspan=\"5\">AZN \u2013 AstraZeneca<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" align=\"center\"><img","protected":false},"excerpt":{"rendered":"<p>Finanzaonline.com &#8211; 12.12.11\/11:05 I titoli europei dei farmaci finiscono sotto la lente di ingrandimento di Credit Suisse, che mette mano alla valutazione di qualche big del settore. Secondo il broker svizzero, il 2012 riserver&agrave; nuove sfide per le case farmaceutiche d&#8217;Europa ma le strategie di diversificazione e di sviluppo nei Paesi emergenti finora adottate e &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14373","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14373"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14373\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}